| Exclusion Criteria: | 1) Subjects with newly diagnosed myeloma
2) Known neoplastic central nervous system (CNS) abnormality
3) Subjects with non-secretory myeloma, plasma cell leukemia, or plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome)
4) Prior allogenic stem cell transplant
5) Subjects receiving bisphosphonates (oral or IV) within 2 weeks before enrollment
6) Evidence of any of the following conditions per subject self report or medical cohort review: - Subjects with prior malignancies (except multiple myeloma, basal cell carcinoma or in situ cervical cancer) may be enrolled if disease free for >/= 5 years - Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before enrollment - Known infection with human immunodeficiency virus (HIV) - Known active infection with Hepatitis B virus or Hepatitis C virus
7) Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
8) </= 30 days since receiving an investigational product or device in another clinical trial. ('Investigational is defined as any drug or device not approved for any indication by the applicable regulatory agency). Current enrollment in another clinical trial is not permitted unless the subject's continued participation in the trial is for long-term follow-up/survival data
9) Subjects must agree to use effective contraception during the treatment period. Female subjects with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days before enrollment. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
10) Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D) |